Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1998-11-30
|
| pubmed:abstractText |
Although the risk of transfusion-transmitted hepatitis has been recently reduced, transfusion-dependent beta-thalassemia patients may still develop liver disease due to viral infection or iron overload. We assessed the frequency and causes of liver dysfunction in a cohort of anti-hepatitis C virus (HCV) negative thalassemics. Of 1,481 thalassemics enrolled in 31 centers, 219 (14.8%) tested anti-HCV- by second-generation assays; 181 completed a 3-year follow-up program consisting of alanine-aminotransferase (ALT) measurement at each transfusion and anti-HCV determination by third-generation enzyme-immunoassay (EIA-3) at the end of study. Serum ferritin levels were determined at baseline and at the end of follow-up. Ten patients were anti-HCV+ by EIA-3 at the end of follow-up. Of them, seven were already positive in 1992 to 1993 when the initial sera were retested by EIA-3, one tested indeterminate by confirmatory assay, and two had true seroconversion (incidence, 4. 27/1,000 person years; risk of infection, 1/7,100 blood units, 95% confidence interval [CI], 1 in 2,000-1 in 71,000 units). At baseline, 67 of 174 thalassemics had abnormal ALT. Of those with normal ALT, seven subsequently developed at least one episode of moderate ALT increase (incidence, 24.6/1,000 person-years). All of the 20 patients with ferritin values >/=3,000 ng/mL had clinically relevant ALT abnormalities, as compared with 53 of 151 with <3,000 ng/mL (P < .005). Hepatic dysfunction is still frequent in thalassemics. Although it is mainly attributable to siderosis and primary HCV infection, the role of undiscovered transmissible agents cannot be excluded.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 1998 by The American Society of Hematology
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
92
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3460-4
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9787188-Adolescent,
pubmed-meshheading:9787188-Adult,
pubmed-meshheading:9787188-Alanine Transaminase,
pubmed-meshheading:9787188-Blood Transfusion,
pubmed-meshheading:9787188-Child,
pubmed-meshheading:9787188-Child, Preschool,
pubmed-meshheading:9787188-Female,
pubmed-meshheading:9787188-Ferritins,
pubmed-meshheading:9787188-Genetic Predisposition to Disease,
pubmed-meshheading:9787188-Hepacivirus,
pubmed-meshheading:9787188-Hepatitis, Viral, Human,
pubmed-meshheading:9787188-Hepatitis C Antibodies,
pubmed-meshheading:9787188-Homozygote,
pubmed-meshheading:9787188-Humans,
pubmed-meshheading:9787188-Incidence,
pubmed-meshheading:9787188-Infant,
pubmed-meshheading:9787188-Infant, Newborn,
pubmed-meshheading:9787188-Iron Overload,
pubmed-meshheading:9787188-Italy,
pubmed-meshheading:9787188-Liver Diseases,
pubmed-meshheading:9787188-Liver Function Tests,
pubmed-meshheading:9787188-Male,
pubmed-meshheading:9787188-Middle Aged,
pubmed-meshheading:9787188-Prospective Studies,
pubmed-meshheading:9787188-Risk,
pubmed-meshheading:9787188-beta-Thalassemia
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia.
|
| pubmed:affiliation |
Centro Trasfusionale e di Immunologia dei Trapianti, Servizio Autonomo per il Prelievo e la Conservazione di Organi e Tessuti, Milano, Italy.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|